drugset / Trial / NCT05949281
Repurposing Colchicine for Reduction of Residual Inflammatory Risk in Type 1 Diabetes
Phase 2
Active not recruiting
102 enrolled
Asger Lund, MD
Juvenile Diabetes Research Foundation · collabUniversity of Copenhagen · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The aim of this clinical trial is to evaluate if colchicine in addition to standard of care improves markers of inflammation and cardiovascular disease in persons with type 1 diabetes. Participants will be assigned to either 0,5 mg colchicine daily or placebo in a 1:1 ratio for 26 weeks with the possibility of an additional 26 week extension of the intervention period. After the treatment period, there will a 5-year follow-up on all available outcome measures via electronic patient records for those who took part in the extension.
Timeline
- Start
- 2023-08-29
- Primary completion
- 2031-01-15
- Completion
- 2031-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Colchicine | Small molecule | 0.5 mg | Oral |